CO2023004102A2 - Variantes de anticuerpos caninos - Google Patents

Variantes de anticuerpos caninos

Info

Publication number
CO2023004102A2
CO2023004102A2 CONC2023/0004102A CO2023004102A CO2023004102A2 CO 2023004102 A2 CO2023004102 A2 CO 2023004102A2 CO 2023004102 A CO2023004102 A CO 2023004102A CO 2023004102 A2 CO2023004102 A2 CO 2023004102A2
Authority
CO
Colombia
Prior art keywords
canine antibody
antibody variants
canine
relates
variants
Prior art date
Application number
CONC2023/0004102A
Other languages
English (en)
Spanish (es)
Inventor
Lisa Marie Bergeron
Henry Luis Campos
Original Assignee
Zoetis Services Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zoetis Services Llc filed Critical Zoetis Services Llc
Publication of CO2023004102A2 publication Critical patent/CO2023004102A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/72—Increased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
CONC2023/0004102A 2020-09-28 2023-03-29 Variantes de anticuerpos caninos CO2023004102A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063084241P 2020-09-28 2020-09-28
PCT/US2021/052338 WO2022067233A2 (en) 2020-09-28 2021-09-28 Canine antibody variants

Publications (1)

Publication Number Publication Date
CO2023004102A2 true CO2023004102A2 (es) 2023-04-05

Family

ID=78599123

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2023/0004102A CO2023004102A2 (es) 2020-09-28 2023-03-29 Variantes de anticuerpos caninos

Country Status (17)

Country Link
US (2) US12612454B2 (cg-RX-API-DMAC10.html)
EP (1) EP4217384A2 (cg-RX-API-DMAC10.html)
JP (1) JP2023543262A (cg-RX-API-DMAC10.html)
KR (1) KR20230079148A (cg-RX-API-DMAC10.html)
CN (1) CN116438196A (cg-RX-API-DMAC10.html)
AR (1) AR123636A1 (cg-RX-API-DMAC10.html)
AU (1) AU2021349301A1 (cg-RX-API-DMAC10.html)
BR (1) BR112023005393A2 (cg-RX-API-DMAC10.html)
CA (1) CA3194936A1 (cg-RX-API-DMAC10.html)
CL (2) CL2023000878A1 (cg-RX-API-DMAC10.html)
CO (1) CO2023004102A2 (cg-RX-API-DMAC10.html)
EC (1) ECSP23030271A (cg-RX-API-DMAC10.html)
IL (1) IL301413A (cg-RX-API-DMAC10.html)
MX (1) MX2023003624A (cg-RX-API-DMAC10.html)
PE (1) PE20231374A1 (cg-RX-API-DMAC10.html)
TW (1) TW202229337A (cg-RX-API-DMAC10.html)
WO (1) WO2022067233A2 (cg-RX-API-DMAC10.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL297287A (en) * 2020-04-17 2022-12-01 Zoetis Services Llc Canine antibody variants
CA3194936A1 (en) * 2020-09-28 2022-03-31 Zoetis Services Llc Canine antibody variants
AU2023289332A1 (en) * 2022-06-21 2024-12-12 Zoetis Services Llc Canine antibody mutants
US20240254231A1 (en) 2023-01-20 2024-08-01 PetMedix Ltd. Therapeutic antibodies

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US6284471B1 (en) 1991-03-18 2001-09-04 New York University Medical Center Anti-TNFa antibodies and assays employing anti-TNFa antibodies
US5698762A (en) 1994-12-09 1997-12-16 Dauerman; Leonard Microwave-assisted pyrolysis of waste polyaromatic hydrocarbons
US20030031671A1 (en) 2001-08-01 2003-02-13 Sydney Welt Methods of treating colon cancer utilizing tumor-specific antibodies
CA2577133A1 (en) 2004-08-19 2006-03-23 Genentech, Inc. Polypeptide variants with altered effector function
US8546543B2 (en) 2004-11-12 2013-10-01 Xencor, Inc. Fc variants that extend antibody half-life
US8367805B2 (en) 2004-11-12 2013-02-05 Xencor, Inc. Fc variants with altered binding to FcRn
US9200079B2 (en) 2004-11-12 2015-12-01 Xencor, Inc. Fc variants with altered binding to FcRn
ES2665954T3 (es) 2010-08-19 2018-04-30 Zoetis Belgium S.A. Anticuerpos anti-NGF y su uso
US8790651B2 (en) 2011-07-21 2014-07-29 Zoetis Llc Interleukin-31 monoclonal antibody
US9617334B2 (en) 2012-06-06 2017-04-11 Zoetis Services Llc Caninized anti-NGF antibodies and methods thereof
AU2014368453B2 (en) 2013-12-20 2020-04-16 Intervet International B.V. Caninized murine anti-canine PD-1 antibodies
EP3866842A4 (en) * 2018-10-18 2022-07-13 Kindred Biosciences, Inc. FC VARIANTS WITH MODIFIED BINDING TO THE NEONATAL FC RECEPTOR (FCRN) FOR VETERINARY USE
JP2022513653A (ja) * 2018-11-28 2022-02-09 ブリストル-マイヤーズ スクイブ カンパニー 修飾された重鎖定常領域を含む抗体
WO2020116560A1 (ja) * 2018-12-05 2020-06-11 株式会社バイカ・セラピュティクス 抗体のFc領域改変体
CN120005022A (zh) * 2019-01-03 2025-05-16 因外泰克斯公司 用于增加治疗剂在犬中的半衰期的组合物及使用方法
IL297287A (en) * 2020-04-17 2022-12-01 Zoetis Services Llc Canine antibody variants
US20220119513A1 (en) 2020-06-08 2022-04-21 Zoetis Services Llc Anti-tgfb antibodies and therapeutic uses thereof
CA3194936A1 (en) 2020-09-28 2022-03-31 Zoetis Services Llc Canine antibody variants

Also Published As

Publication number Publication date
US20260193334A1 (en) 2026-07-09
EP4217384A2 (en) 2023-08-02
CL2024000628A1 (es) 2024-07-19
TW202229337A (zh) 2022-08-01
CN116438196A (zh) 2023-07-14
BR112023005393A2 (pt) 2023-04-25
IL301413A (en) 2023-05-01
WO2022067233A2 (en) 2022-03-31
WO2022067233A3 (en) 2022-05-27
AR123636A1 (es) 2022-12-28
KR20230079148A (ko) 2023-06-05
PE20231374A1 (es) 2023-09-07
CA3194936A1 (en) 2022-03-31
US12612454B2 (en) 2026-04-28
CL2023000878A1 (es) 2023-10-20
ECSP23030271A (es) 2023-07-31
MX2023003624A (es) 2023-04-11
JP2023543262A (ja) 2023-10-13
AU2021349301A1 (en) 2023-08-24
US20240010716A1 (en) 2024-01-11

Similar Documents

Publication Publication Date Title
CL2022002857A1 (es) Variantes de anticuerpos caninos
CL2023003376A1 (es) Variantes de anticuerpos felinos
ECSP23030271A (es) Variantes de anticuerpos caninos
CL2024001562A1 (es) Mutaciones en regiones constantes de anticuerpos caninos.
ECSP23030307A (es) Variantes de anticuerpos felinos
CL2024001519A1 (es) Mutaciones en regiones constantes de anticuerpos felinos.
CO2023007146A2 (es) Variantes de anticuerpos bovinos
EA202191806A1 (ru) Антитело против человеческого il-4ra и его применение
SA523450918B1 (ar) أجسام مضادة للنكتين-4 واستخداماتها
CL2024000321A1 (es) Antagonistas de lpar1 y usos de estos
PE20230259A1 (es) Anticuerpos anti-tgf-beta con selectividad de isoforma y metodos de uso
MX2024006208A (es) Anticuerpo anti-trem2 y usos del mismo.
EA201991319A1 (ru) Вакцины аттенуированного свиного гриппа и способы их изготовления и применения
MX2025002524A (es) Mutantes de anticuerpos equinos
EA201991614A1 (ru) СПЕЦИФИЧНЫЕ К ИЗОФОРМЕ, ПЕРМИССИВНЫЕ ПО ОТНОШЕНИЮ К КОНТЕКСТУ ИНГИБИТОРЫ TGFβ1 И ИХ ПРИМЕНЕНИЕ
CO2024016060A2 (es) Anticuerpos anti-ly6e, inmunoconjugados y usos de estos
TR202104726A2 (tr) Köfte form maki̇nasinda yeni̇li̇k